BRAF and neoplasm: Approximately one third of pts included in this study had been included in previous reports.Of the 2 pts that responded to treatment with BRAF sequence variants, 1 had a p.Asp549Gly variant and the other had the p.Val600Glu variant, but at a low copy number in the tumor sample.